A phenomic and genomic approach to identifying pharmaceutical targets for the amelioration of hematopoietic deficit

点击翻译按钮获取中文摘要

Mice and humans are genetically and physiologically similar, and are afflicted by many of the same diseases. By introducing random DNA mutations into the germline, mice with diseaseassociated characteristics can be generated, allowing the subsequent identification of genes involved in particular human disease processes. This project will utilise cutting-edge genetic technologies to discover genes that regulate production of the body�s principal blood clotting agents: platelets. This is of particular clinical and commercial importance since a reduction in platelet numbers is the life-threatening result of congenital and autoimmune diseases, viral infections (e.g. HIV) and cancer chemotherapy.